Azacitidine is used for treatment of patients with myelodysplastic syndrome subtypes; refractory anemia with ringed or excess blasts or acute myleogenous leukemia [24].
However, within 17 months, the patient was diagnosed with myelodysplastic syndrome with refractory anemia with excess blasts (MDS-RAEB).
At the time of investigation, 35 patients had Refractory Anemia (RA), 33 RARS and 54 Refractory Anemia with Excess Blasts (RAEB).
A decrease in Chk1 RNA has also been observed in patients with refractory anemia with excess blasts, further supporting a role for Chk1 in clinical anemia.
Moreover, a decrease in Chk1 RNA has been observed in patients with refractory anemia with excess blasts, further supporting an important role for Chk1 status in clinical anemia [29].
We have compared the gene expression levels of ABCB7 between 35 patients with refractory anemia (RA), 33 patients with RARS, 54 patients with RA and excess blasts (RAEB), and 16 healthy controls (Table 1; Figure 1A).
The patients include refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML), with a median International Prognostic Scoring System (IPSS) score of 1 (range 0 3), and a median blast count of 4.5% (range 0 26%).
We have investigated ABCB7 gene expression levels in the CD34+ cells of 122 MDS cases, comprising 35 patients with refractory anemia (RA), 33 patients with RARS and 54 patients with RA with excess blasts (RAEB), and in the CD34+ cells of 16 healthy controls.
13 Hypocellular MDS without excess blasts is difficult to differentiate from a diagnosis of aplastic anemia.
A bone marrow biopsy showed hypercellularity with granulocytic and megakaryocytic hyperplasia, no excess blasts, and moderate fibrosis on reticulin staining.
